ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 1858 • ACR Convergence 2025

    Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.

    Aurélien Chepy1, Marie-Elise Martel1, Solange Vivier1, Meryem Tardivel2, Antonino Bongiovanni2, Marie Mistretta1, Maxime Secq1, Lucile Guilbert3, Eric HACHULLA4, Sylvain Dubucquoi5, David Launay1 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, 2Univ. Lille, BioImaging Center Lille-Nord de France (BICeL), Lille, France., Lille, France, 3CHU Lille, Institut d'Immunologie, Lille, France., Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, 5Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France

    Background/Purpose: Antinuclear autoantibodies (ANA) are robust biomarkers for the diagnosis and prognosis of systemic sclerosis (SSc), but their role in pathogenesis is still uncertain. Recent…
  • Abstract Number: 1037 • ACR Convergence 2025

    Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis

    Zixing Liu1, Adrianne Woods2, Julie Paik2, Laura Hummers2, Scott Zeger1, Ami Shah2 and Ji Soo Kim3, 1Johns Hopkins Biostatistics, Baltimore, MD, 2Johns Hopkins Rheumatology, Baltimore, MD, 3Johns Hopkins, Baltimore, MD

    Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
  • Abstract Number: 0691 • ACR Convergence 2025

    Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis

    Brian Lee1, Shufeng Li1, Srijana Davuluri2, Jennifer Lee1 and Lorinda Chung2, 1Stanford University, Stanford, 2Stanford University, Stanford, CA

    Background/Purpose: Elevated acute phase reactants such as platelets and C-reactive protein (CRP) have been used as inclusion criteria to enrich systemic sclerosis (SSc) clinical trials…
  • Abstract Number: 2482 • ACR Convergence 2025

    Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology

    Francesco Bonomi1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4, Corrado Campochiaro5, Roberto Caporali6, Veronica Codullo7, Maria Antonietta D'Agostino8, Lorenzo Dagna9, Rossella De Angelis10, Giacomo de Luca11, Dilia Giuggioli12, Serena Guiducci13, Florenzo Iannone14, Francesca Ingegnoli15, Carlomaurizio Montecucco7, Valeria Riccieri16, Clodoveo Ferri17, Marco Matucci-Cerinic18 and Silvia Bellando Randone19, 1University Hospital Careggi, Florence, Florence, Toscana, Italy, 2University of Zurich, Zurich, Switzerland, 3Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, 4Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, 5IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 6University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, 7Policlinico San Matteo, Pavia, Pavia, Italy, 8Catholic University of the Sacred Heart, Rome, Rome, Italy, 9Ospedale San Raffaele, Milano, Italy, 10Polytechnic University of Marche, Ancona, Ancona, Italy, 11Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, 12Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, 13Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, 14Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, 15Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, Università degli Studi di Milano, Milan, Italy, Milan, Italy, 16Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, 17University of Modena and Reggio Emilia, Modena, Modena, Italy, 18University San Raffaele Milano, Milano, Milan, Italy, 19University of Florence, Florence, Italy

    Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
  • Abstract Number: 1591 • ACR Convergence 2025

    Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis

    Zsuzsanna McMahan1, Claudia Pedroza2, Katie Lee3, Bingrui Chen3, Ami Shah4, Jody Hooper5, Srinivas Puttapaka6, Livia Casciola-Rosen7 and Subhash Kulkarni8, 1UT Health Houston, Houston, TX, 2UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, 3UTHealth Houston, Houston, TX, 4Johns Hopkins Rheumatology, Baltimore, MD, 5Stanford University, Stanford, CA, 6BIDMC/Harvard, Boston, MA, 7Johns Hopkins University, Baltimore, MD, 8BIDMC, Boston, MA

    Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
  • Abstract Number: 0997 • ACR Convergence 2025

    Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 

    Olivia Pryor1, Catalina Burbano2, Nathaniel Bagge2, Rutuja Kulkarni2, Heather F. Jones2, Livio Dukaj2, Shoshana M.K. Bloom2, Jackson Lirette2, Rachel Lent2, Prachi Dhanania2, Nicole A. Ladd2, Ryan Kritzer2, Hana Husic2, Shobitha Jillella2, Candace R. Perullo2, Jinyu Zhu2, Teagan J. Parsons2, Ira Jain2, Rakshika Balasubramaniyam2, Kenneth L. Jahan2, Vivin Karthik2, Alexander Cristofaro1, Chandan K. Pavuluri2, Jenna LaBelle2, Laurie Barefoot2, Shrikanta Chattopadhyay2, Kim M. Cirelli2, Mollie M. Jurewicz2, Andrew P. Ferretti2 and Cagan Gurer2, 1TScan Therapeutics, Waltham, 2TScan Therapeutics, Waltham, MA

    Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
  • Abstract Number: 0688 • ACR Convergence 2025

    Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study

    Benjamin Chaigne1, Alexandre bense2, Frédérique Aubourg3, Christian AGARD4, Yannick Allanore5, Alice berezne1, Gregory Pugnet6, Eric Hachulla7, Vincent Cottin8, Arnaud Hot8, bertrand Dunogue1, Anuxcy Kanagaratnam2, Sylvain Palat9, Alain Lescoat10, Sabine berthier11, Emmanuel Chatelus12, Sébastien Rivière13, David Launay14, Marie-Elise Truchetet15, Anh-Tuan Dinh-Xuan3 and Luc Mouthon1, 1Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, 2AP HP, Paris, France, 3Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5Université Paris Cité, Paris, France, 6CHU, Montpelliers, France, 7CHU, Lilles, France, 8CHU, Lyon, France, 9Limoges, Limoges, France, 10CHU Rennes - University Rennes, Rennes, France, 11CHU, Dijon, France, 12Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, 13AP HP, Parsi, France, 14Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, 15Bordeaux University Hospital, Bordeaux, France

    Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
  • Abstract Number: 2478 • ACR Convergence 2025

    Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients

    Daniel Barnett1, Alyssa Rosek2, Yi-Chen Chen3, Alexander Cai4, Deren Esencan5, Sophia Matossian6, Christine Goudsmit7, Haley Havrilla8, Anwesha Sanyal9, Julie Sturza10, Pei-Suen Tsou6, Kathryn Torok9 and Jessica Turnier11, 1Division of Pediatric Rheumatology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, 4Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 51. Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, 6University of Michigan, Ann Arbor, MI, 7University of Michigan, Ann Arbor, 8Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, 9University of Pittsburgh, Pittsburgh, PA, 10Division of Pediatric Rheumatology, CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 11University of Michigan, Saline, MI

    Background/Purpose: Vasculopathy is a central driving clinical, histopathologic and pathogenic feature of juvenile systemic scleroderma (jSSc), juvenile dermatomyositis (JDM) and juvenile scleroderma-overlap syndrome (jOverlap). While…
  • Abstract Number: 1590 • ACR Convergence 2025

    Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients

    Yuzo Ikari1, Poulami Dey2, James St. Clair3, Anna Webber4, Caroline Foster5, Yi-Chen Chen5, Ramadan Ali6, Dinesh Khanna7, David Fox8 and Pei-Suen Tsou7, 1Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan, 2Michigan Medicine, Ann Arbor, MI, 3University of Michigan, Ann Arbor, 4Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 5Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, 6University of Michigan, Ann Arobr, MI, 7University of Michigan, Ann Arbor, MI, 8University of Michigan, Dexter, MI

    Background/Purpose: Soluble CD13 (sCD13), released by the cleavage of cell surface CD13 by matrix metalloproteinase-14 (MMP14), has potent proinflammatory, angiogenic, and arthritogenic activities. The receptors…
  • Abstract Number: 0972 • ACR Convergence 2025

    Prominent endothelial senescence in systemic sclerosis skin

    Poulami Dey1, William D Brodie2, Megan N Mattichak3, Alexander Cai3, Qi Wu4, Johann Gudjonsson5, Dinesh Khanna5, John Varga5 and Pei-Suen Tsou5, 1Michigan Medicine, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 4Michigan Medicine, Ann Arbor, 5University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is characterized by extensive damage of the microvessels in multiple organs. We and others showed that endothelial cells (ECs) isolated from…
  • Abstract Number: 0685 • ACR Convergence 2025

    Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention

    Areeka Memon1, Monique Hinchcliff2 and Amir Masoud3, 1Yale New Haven Health, New Haven, CT, 2Yale School of Medicine, Westport, CT, 3Hartford Healthcare, hartford

    Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
  • Abstract Number: 2471 • ACR Convergence 2025

    Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use

    Borja del Carmelo Gracia Tello1, Gema María Lledó Ibáñez2, Luis Sáez Comet3 and Eduardo Ramos ibáñez4, 1Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Capillary.io, Zaragoza, Aragon, Spain

    Background/Purpose: Nailfold capillaroscopy is a key tool in the early diagnosis of systemic sclerosis and related disorders. However, incorrect image acquisition can lead to misclassification…
  • Abstract Number: 1589 • ACR Convergence 2025

    Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation

    Punchalee Kaenmuang1, Nina Goldman2, Arthihai Srirangan1, Fiammetta Danzo1, Wing-Ho Yip1, Ali Taki3, Shereen Boreland1, Benedetta Vitri1, Carmel JW. Stock1, Christopher Denton4, Athol U. Wells1, Voon H. Ong5, Piersante Sestini6 and Elisabetta A. Renzoni1, 1Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy’s and St Thomas’ National Health Service Foundation Trust, London, England, United Kingdom, 2Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, 3Royal Free Hospital, London, England, United Kingdom, 4University College London, UK, London, United Kingdom, 5Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 6Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Toscana, Italy

    Background/Purpose: Nintedanib slows the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, potential high discontinuation rates due to adverse side-effects raise concerns about its…
  • Abstract Number: 0971 • ACR Convergence 2025

    Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3

    Neha Khanna1, Alyssa Rosek1, Alexander Cai1, Olesya Plazyo2, Johann Gudjonsson2, Dinesh Khanna2 and Pei-Suen Tsou2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by excessive collagen production, leading to the thickening and hardening of skin and internal organs.…
  • Abstract Number: 0682 • ACR Convergence 2025

    Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study

    Alex Luta1, Saloni Mitchell2 and Virginia Steen3, 1Hospital for Special Surgery, New York, NY, 2Mount Sinai West and Morningside, New York, NY, 3Georgetown University School of Medicine, Washington, DC

    Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology